ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1045
-0,50%
Bitcoin
66.898,20
2,54%
Brent Oil
83,73
0,63%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Entera Bio Ltd (ENTX)

  7. Entera Bio Ltd (ENTX) Notícias

ENTX

Entera Bio (ENTX)

Entera Bio Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ENTX
DataHoraFonteTítuloCódigoCompanhia
15/05/202409:00GlobeNewswire Inc.Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board MemberNASDAQ:ENTXEntera Bio Ltd
13/05/202408:00GlobeNewswire Inc.Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024NASDAQ:ENTXEntera Bio Ltd
10/05/202417:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ENTXEntera Bio Ltd
10/05/202417:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
10/05/202417:10GlobeNewswire Inc.Entera Bio Reports Q1 2024 Financial Results and Provides Business UpdatesNASDAQ:ENTXEntera Bio Ltd
08/04/202409:30GlobeNewswire Inc.Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral ResearchNASDAQ:ENTXEntera Bio Ltd
26/03/202409:30GlobeNewswire Inc.Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 MonthsNASDAQ:ENTXEntera Bio Ltd
20/03/202409:00GlobeNewswire Inc.Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel SyndromeNASDAQ:ENTXEntera Bio Ltd
08/03/202418:25Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ENTXEntera Bio Ltd
08/03/202418:12Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ENTXEntera Bio Ltd
08/03/202418:05GlobeNewswire Inc.Entera Bio Announces Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:ENTXEntera Bio Ltd
04/03/202410:30GlobeNewswire Inc.Entera Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:ENTXEntera Bio Ltd
15/02/202419:10Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ENTXEntera Bio Ltd
15/02/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ENTXEntera Bio Ltd
14/02/202408:05Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ENTXEntera Bio Ltd
02/02/202418:17Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ENTXEntera Bio Ltd
30/01/202410:30GlobeNewswire Inc.Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ENTXEntera Bio Ltd
16/01/202410:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
02/01/202419:19Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ENTXEntera Bio Ltd
26/12/202310:00GlobeNewswire Inc.Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025NASDAQ:ENTXEntera Bio Ltd
29/11/202310:30GlobeNewswire Inc.Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide PlatformNASDAQ:ENTXEntera Bio Ltd
14/11/202309:30GlobeNewswire Inc.Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in DevelopmentNASDAQ:ENTXEntera Bio Ltd
09/11/202316:30GlobeNewswire Inc.Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for OsteoporosisNASDAQ:ENTXEntera Bio Ltd
16/10/202309:00GlobeNewswire Inc.Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual MeetingNASDAQ:ENTXEntera Bio Ltd
12/09/202309:30GlobeNewswire Inc.Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption SyndromesNASDAQ:ENTXEntera Bio Ltd
05/09/202309:00GlobeNewswire Inc.Entera Bio to Participate in Upcoming Investor ConferencesNASDAQ:ENTXEntera Bio Ltd
24/08/202309:11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
16/08/202309:30GlobeNewswire Inc.Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual MeetingNASDAQ:ENTXEntera Bio Ltd
15/08/202317:10Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ENTXEntera Bio Ltd
11/08/202317:05GlobeNewswire Inc.Entera Bio Announces Q2 2023 Financial Results and Corporate UpdatesNASDAQ:ENTXEntera Bio Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:ENTX

Seu Histórico Recente

EU
BNPLX
BNP Paribas SA Bnp Parib...
LSE
SORB
Sorbic
COIN
INFXEUR
AMEX
HYLG
Global X Health Care Cov...
BOV
PETRS365
PETRS365 Ex:33,87
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados